2022年11月,天津医科大学肿瘤研究所张海洋教授团队在学术期刊发表题为“Single cell sequencing revealed the mechanism of PD-1 resistance affected by the expression profile of peripheral blood immune cel…
However, PD-1/PD-L1 could also prevent the activation of T cells in the tumor and thus result in immune resistance [5]. PD-1/PD-L1 blockade is a breakthrough in cancer immunotherapy, and it has been trialed in a broad range of malignancies in the preclinical or clinical stage, ...
mechanismPD‐1/PD‐L1resistancestudy and analysisImmunocheckpoint proteins of tumor infiltrating lymphocytes play an important role in tumor prognosis in the course of tumor clinicopathology. PD(Programmed cell death protein 1) is an important immunosuppressive molecule. By binding to PD㎜1 (programmed...
Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4:127-37.
[6].Taube J M, Anders R A, Young G D, et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape[J]. Science Translational Medicine, 2012, 4(127).DOI:10.1126/scitranslmed.3003689 ...
2. Chaganty B K R, Qiu S, Gest A, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion[J].Cancer Letters, 2018, 430: 47–56. ...
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37. Article CAS PubMed PubMed Central Google Scholar Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, ...
functions and acts as a tumor suppressor or promoter depending on the context20,21,22. In addition, the precise mechanism of immune suppression and anti-PD-1/PD-L1 resistance by tumor-associated collagen has not been comprehensively investigated. ...
we describe an alternative mechanism of PD-L1 activity involving its secretion in tumor-derived exosomes. Removal of exosomal PD-L1 inhibits tumor growth, even in models resistant to anti-PD-L1 antibodies. Exosomal PD-L1 from the tumor suppresses T cell activation in the draining lymph node. Sy...
The PDCD1-encoded immune checkpoint receptor PD-1 is a key tumor suppressor in T cells that is recurrently inactivated in T cell non-Hodgkin lymphomas (T-NHLs). The highest frequencies of PDCD1 deletions are detected in advanced disease, predicting infer